138 related articles for article (PubMed ID: 7991885)
21. A twelve-week comparison of salmeterol and salbutamol in the treatment of mild-to-moderate asthma: a Canadian multicenter study.
Boulet LP; Laviolette M; Boucher S; Knight A; Hébert J; Chapman KR
J Allergy Clin Immunol; 1997 Jan; 99(1 Pt 1):13-21. PubMed ID: 9003206
[TBL] [Abstract][Full Text] [Related]
22. Salmeterol versus theophylline in the treatment of asthma.
Pollard SJ; Spector SL; Yancey SW; Cox FM; Emmett A
Ann Allergy Asthma Immunol; 1997 May; 78(5):457-64. PubMed ID: 9164358
[TBL] [Abstract][Full Text] [Related]
23. Salmeterol xinafoate in children on high dose inhaled steroids.
Russell G; Williams DA; Weller P; Price JF
Ann Allergy Asthma Immunol; 1995 Nov; 75(5):423-8. PubMed ID: 7583864
[TBL] [Abstract][Full Text] [Related]
24. Asthma control during long-term treatment with regular inhaled salbutamol and salmeterol.
Taylor DR; Town GI; Herbison GP; Boothman-Burrell D; Flannery EM; Hancox B; Harré E; Laubscher K; Linscott V; Ramsay CM; Richards G
Thorax; 1998 Sep; 53(9):744-52. PubMed ID: 10319056
[TBL] [Abstract][Full Text] [Related]
25. [Therapy of nocturnal asthma: salmeterol versus nocturnal administration of retard theophylline--comparison of effectiveness and tolerance].
Ukena D; Koper I; Braun H; Leutz M; Schlimmer P; Sybrecht GW
Pneumologie; 1997 Mar; 51(3):317-23. PubMed ID: 9173422
[TBL] [Abstract][Full Text] [Related]
26. Salmeterol xinafoate in asthmatic patients under consideration for maintenance oral corticosteroid therapy. UK Study Group.
Boyd G
Eur Respir J; 1995 Sep; 8(9):1494-8. PubMed ID: 8575574
[TBL] [Abstract][Full Text] [Related]
27. Salmeterol xinafoate in the treatment of mild to moderate asthma in primary care. UK Study Group.
Jones KP
Thorax; 1994 Oct; 49(10):971-5. PubMed ID: 7974313
[TBL] [Abstract][Full Text] [Related]
28. Inhaled salmeterol in the treatment of patients with moderate to severe reversible obstructive airways disease--a 3-month comparison of the efficacy and safety of twice-daily salmeterol (100 micrograms) with salmeterol (50 micrograms).
Palmer JB; Stuart AM; Shepherd GL; Viskum K
Respir Med; 1992 Sep; 86(5):409-17. PubMed ID: 1361068
[TBL] [Abstract][Full Text] [Related]
29. Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy.
Fish JE; Israel E; Murray JJ; Emmett A; Boone R; Yancey SW; Rickard KA
Chest; 2001 Aug; 120(2):423-30. PubMed ID: 11502639
[TBL] [Abstract][Full Text] [Related]
30. [Salmeterol improves the control of disease in patients with moderate asthma. A comparative study of inhaled salmeterol 50 mg and salbutamol depot tablets 8 mg, both administered twice daily].
Ringbaek TJ; Søes-Petersen U; Christensen M; Iversen ET; Rasmussen FV
Ugeskr Laeger; 1996 Jul; 158(27):3940-3. PubMed ID: 8701511
[TBL] [Abstract][Full Text] [Related]
31. Salmeterol in paediatric asthma.
Byrnes C; Shrewsbury S; Barnes PJ; Bush A
Thorax; 2000 Sep; 55(9):780-4. PubMed ID: 10950898
[TBL] [Abstract][Full Text] [Related]
32. A 4-week comparison of salmeterol and terbutaline in adult asthma.
Hermansson BA; Jenkins RJ
Allergy; 1995 Jul; 50(7):551-8. PubMed ID: 8588686
[TBL] [Abstract][Full Text] [Related]
33. The efficacy and safety of salmeterol compared to theophylline: meta-analysis of nine controlled studies.
Davies B; Brooks G; Devoy M
Respir Med; 1998 Feb; 92(2):256-63. PubMed ID: 9616522
[TBL] [Abstract][Full Text] [Related]
34. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group.
Greening AP; Ind PW; Northfield M; Shaw G
Lancet; 1994 Jul; 344(8917):219-24. PubMed ID: 7913155
[TBL] [Abstract][Full Text] [Related]
35. Twelve month comparison of salmeterol and salbutamol as dry powder formulations in asthmatic patients. European Study Group.
Lundback B; Rawlinson DW; Palmer JB
Thorax; 1993 Feb; 48(2):148-53. PubMed ID: 8493629
[TBL] [Abstract][Full Text] [Related]
36. Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma.
Bateman ED; Kornmann O; Schmidt P; Pivovarova A; Engel M; Fabbri LM
J Allergy Clin Immunol; 2011 Aug; 128(2):315-22. PubMed ID: 21807250
[TBL] [Abstract][Full Text] [Related]
37. Inhaled salmeterol and albuterol in asthmatic patients receiving high-dose inhaled corticosteroids.
Lai CK; Chan CH; Ho SS; Hui AC; Lai KN
Chest; 1995 Jul; 108(1):36-40. PubMed ID: 7606988
[TBL] [Abstract][Full Text] [Related]
38. Salmeterol in nocturnal asthma: a double blind, placebo controlled trial of a long acting inhaled beta 2 agonist.
Fitzpatrick MF; Mackay T; Driver H; Douglas NJ
BMJ; 1990 Dec; 301(6765):1365-8. PubMed ID: 1980220
[TBL] [Abstract][Full Text] [Related]
39. Salmeterol plus theophylline combination therapy in the treatment of COPD.
ZuWallack RL; Mahler DA; Reilly D; Church N; Emmett A; Rickard K; Knobil K
Chest; 2001 Jun; 119(6):1661-70. PubMed ID: 11399688
[TBL] [Abstract][Full Text] [Related]
40. Salmeterol: an inhaled beta 2-agonist with prolonged duration of action.
Lötvall J; Svedmyr N
Lung; 1993; 171(5):249-64. PubMed ID: 8105155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
